According to a recent report by
Coherent Market Insights, the global scopolamine market is projected to be valued
at USD 516.2 million in 2025 and is expected to soar to approximately USD 797.4
million by 2032, growing at a remarkable CAGR of 6.4% from 2025 to 2032.
Ask
for Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1965
Global Scopolamine Market Key
Takeaways
• The global scopolamine market
size is set to grow from US$ 516.2 Mn in 2025 to US$ 797.4 Mn by 2032,
exhibiting a CAGR of 6.4%.
• Based on dosage form, tablets segment is expected to account
for a prominent 35.6% of Scopolamine market
share in 2025.
• By distribution channel, hospital pharmacies segment will
likely account for around USD 156.15 Mn in 2025.
• North America, spearheaded by the United States, is set to
dominate the global scopolamine market, accounting for a share of 37.3% in
2025. This is attributable to rising prevalence of motion sickness and
increasing usage of scopolamine in post-operative care.
• As per Coherent Market Insights’ latest scopolamine market research report, Asia
Pacific is anticipated to witness the fastest growth owing to rising prevalence
of motion sickness, expanding pharmaceutical sector, and growing awareness
about advanced anticholinergic therapies.
• Latest scopolamine market
analysis predicts China and India to become happy hunting grounds for
scopolamine manufacturers, considering the huge patient pool and growing health
awareness.
Increasing Cancer Prevalence Spurring
Growth
A new report by Coherent Market
Insights outlines significant trends in the scopolamine market. One of the
prominent trends expected to propel growth of scopolamine industry is the
rising cases of cancer.
The world is witnessing an alarming
rise in the cases of different types of cancer, and the trend will likely
persist. According to the World Health Organization (WHO), around 35 million
new cancer cases are predicted in 2050. This increasing cancer prevalence is
expected to fuel scopolamine market demand.
Scopolamine can help manage nausea
and vomiting associated with cancer surgeries and chemotherapy treatments. It
has the potential to effectively treat chemotherapy-induced nausea and vomiting
(CINV). Thus, rise in cancer cases will directly impact the scopolamine market growth
in the coming years.
Ask
for Customization Report: https://www.coherentmarketinsights.com/insight/request-customization/1965
Side Effects and Availability of
Substitutes Limited Market Growth
Scopolamine can cause side effects
like blurred vision, dry mouth, hallucination, pruritus, and anhidrosis. As a
result, many patients refrain from consuming this medicine, thereby limiting scopolamine market growth.
Availability of other anticholinergic
drugs is also limiting growth of the scopolamine market. Many patients prefer
to use alternative anticholinergic drugs like atropine, promethazine, and
meclizine to manage motion sickness, vertigo, and other conditions. This
reduces the overall demand for scopolamine.
Expanding Therapeutic Applications
Creating New Growth Opportunities
Although scopolamine is primarily
used to treat motion sickness, ongoing research is expanding its application
area. This is expected to create new growth opportunities for the industry in
the coming years.
Perrigo, Novartis AG, and other
companies are exploring scopolamine for treating various conditions, including
depression and Parkinson’s disease. These expanding therapeutic applications
will likely open new revenue-generation opportunities for companies.
Emerging Scopolamine Market Trends
A study published in the National
Library of Medicine revealed that transdermal scopolamine patches have strong
anti-emetic effects. They can effectively prevent postoperative nausea and
vomiting (PONV) without minimal side effects. Ease of use and excellent safety
profiles of scopolamine patches and sprays are also making them popular.
Rising medical tourism, especially
across nations like India and the United States, is acting as a catalyst for
sales growth. Many patients travel to these nations for affordable and
effective surgical treatments. This will likely create a higher scopolamine demand.
Analyst’s
View
“The global scopolamine
market value is set to increase steadily, driven primarily by rising
prevalence of motion sickness and cancer, advancements in delivery systems, and
expanding therapeutic applications,” said senior analyst Ghanshyam Shrivastava. “Companies
that invest in R&D and tailor solutions for emerging markets like India,
China, and the United States will likely gain a competitive edge in the
forthcoming period.”
Competitor Insights
Key companies listed in scopolamine market report:
– Alchem International
– Integra LifeSciences
Holding Corporation
– Alkaloids Corporation
– Boehringer Ingelheim
– Caleb Pharmaceuticals,
Inc.
– Centroflora Group
– Fine Chemicals Corporation
– GlaxoSmithKline plc
– Henan Fusen Pharmaceutical
Co., Ltd.
– Mylan N.V. (part of
Viatris)
– Novartis AG
– Pfizer Inc.
– Pharmaceutical Associates,
Inc.
– Phytex Australia
– Sun Pharmaceutical
Industries Ltd.
– Teva Pharmaceutical
Industries Ltd.
Key Developments
In August 2024, Zydus Lifesciences Limited
received final approval for Scopolamine Transdermal System 1 mg/3 days from the
U.S. Food and Drug Administration (FDA). The newly approved system is intended
to prevent vomiting and nausea after anesthesia, surgery, and narcotic pain
medicines. It has the potential to prevent vomiting and nausea caused by motion
sickness.
In October 2023, Defender Pharmaceuticals
Inc. collaborated with NASA to initiate two Phase 2 clinical studies
investigating DPI-386’s ability to mitigate G-transition induced motion
sickness as well as improve sensorimotor performance.
In September 2023, Defender Pharmaceuticals
Inc.’s New Drug Application for Intranasal Scopolamine Gel for prevention of
vomiting and nausea induced by motion in adults was accepted by the U.S. FDA.
The new medication is intended to tackle the growing motion sickness burden.
Buy
this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1965
Detailed Segmentation-
By Dosage Form:
- Tablet
- Syrup
- Injection
- Patch
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Related Reports:
The Global Tablet
Market is estimated to be valued at USD 57.52
Billion in 2025 and is expected to reach US$ 75.24 Bn, exhibiting a compound
annual growth rate (CAGR) of 3.9% from 2025 to 2032.
The high
fructose corn syrup market is estimated to be
valued at USD 9.40 Bn in 2025 and is expected to reach USD 10.80 Bn by 2032,
exhibiting a compound annual growth rate (CAGR) of 2.0% from 2025 to 2032.
About Us:
Coherent Market Insights leads into data and
analytics, audience measurement, consumer behaviors, and market trend analysis.
From shorter dispatch to in-depth insights, CMI has exceled in offering
research, analytics, and consumer-focused shifts for nearly a decade. With
cutting-edge syndicated tools and custom-made research services, we empower
businesses to move in the direction of growth. We are multifunctional in our
work scope and have 450+ seasoned consultants, analysts, and researchers across
26+ industries spread out in 32+ countries.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: + 12524771362
UK: +442039578553
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter
